ArticleMikrochimica acta2026
Development of an ligase chain reaction-fluorescence-SERS multimodal biosensing workflow for ultrasensitive detection and single-base discrimination of KRAS ctDNA.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A dual-modality biosensing platform integrating ligase chain reaction (LCR), fluorescence monitoring, and surface-enhanced Raman scattering (SERS) was developed. The LCR step ensures high-fidelity enzymatic amplification, enabling precise discrimination of single-base mismatches at the KRAS locus. Real-time fluorescence using 20 nm gold magnetic nanoparticles provides rapid quantitative evaluation, while SERS analysis on nanostructured OnSpec-Lite bimetallic chips offers molecular-fingerprint confirmation. Under optimized conditions (30 cycles, 60 °C), the biosensor achieved a calculated limit of detection (LOD) of 1.03 fM for SERS and 11.94 fM for fluorescence detection, with corresponding limits of quantification (LOQ) of 3.12 fM and 36.17 fM, respectively. Derived from the linear regression of the SERS calibration curve (y = 73.77x + 871.1; R2 = 0.9617), a linear concentration range of 1 pM to 1000 nM was obtained. Meanwhile, the fluorescence calibration yielded a linear range of 100 pM to 1000 nM (y = 0.069x + 4.848; R2 = 0.8705). Experimentally, the lowest validated ctDNA concentrations detected were 1 pM for SERS and 100 pM for fluorescence. Both detection systems demonstrated high reproducibility, with relative standard deviations (RSDs) below 10%. Furthermore, the platforms maintained analytical robustness in 1/10 and 1/5 serum dilutions, successfully mitigating matrix interference while preserving distinctive Raman signatures. This study introduces a proof-of-concept analytical framework that bridges the high specificity of enzymatic ligation with the ultra-sensitive transduction of nanoplasmonic detection. By combining real-time optical quantification with confirmatory vibrational spectroscopy, the system minimizes false positives and provides cross-validated results essential for high-stakes diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.